WO2009035497A3 - Disease related cysteine modifications and uses thereof - Google Patents

Disease related cysteine modifications and uses thereof Download PDF

Info

Publication number
WO2009035497A3
WO2009035497A3 PCT/US2008/009496 US2008009496W WO2009035497A3 WO 2009035497 A3 WO2009035497 A3 WO 2009035497A3 US 2008009496 W US2008009496 W US 2008009496W WO 2009035497 A3 WO2009035497 A3 WO 2009035497A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrosoglutathione
thiol groups
chemical entity
bowel disease
present
Prior art date
Application number
PCT/US2008/009496
Other languages
French (fr)
Other versions
WO2009035497A2 (en
Inventor
Tor C Savidge
Original Assignee
Tor C Savidge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tor C Savidge filed Critical Tor C Savidge
Publication of WO2009035497A2 publication Critical patent/WO2009035497A2/en
Publication of WO2009035497A3 publication Critical patent/WO2009035497A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses a role for s-nitrosoglutathione in the loss of epithelial barrer integrity. The present invention is further directed to examining the therapeutic value s-nitrosoglutathione and/or a chemical entity that modifies cysteine thiol groups in regulation of intestinal mucosal integrity, function, inflammation, and pain by establishing animal models. This use of s-nitrosoglutathione and/or a chemical entity that modifies cysteine thiol groups provides a novel strategy for therapeutic intervention of pathologies associated with inflammatory barrier disorder such as inflammatory bowel disease, functional bowel disease, and infectious diarrheal disease.
PCT/US2008/009496 2007-08-08 2008-08-08 Disease related cysteine modifications and uses thereof WO2009035497A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96396907P 2007-08-08 2007-08-08
US60/963,969 2007-08-08

Publications (2)

Publication Number Publication Date
WO2009035497A2 WO2009035497A2 (en) 2009-03-19
WO2009035497A3 true WO2009035497A3 (en) 2009-08-06

Family

ID=40452741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009496 WO2009035497A2 (en) 2007-08-08 2008-08-08 Disease related cysteine modifications and uses thereof

Country Status (1)

Country Link
WO (1) WO2009035497A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US10501771B2 (en) 2011-11-08 2019-12-10 The Board Of Regents Of The University Of Texas System Methods and uses for metabolic profiling for Clostridium difficile infection
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SAVIDGE, T. C. ET AL.: "Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione", GASTROENTEROLOGY, vol. 132, no. 4, February 2007 (2007-02-01), pages 1344 - 1358 *
SAVIDGE, T. C. ET AL.: "Starring roles for astroglia in barrier pathologies of gut and brain", LAB. INVEST., vol. 87, July 2007 (2007-07-01), pages 731 - 736 *
SU, L. ET AL.: "Got guts? Need nerve!", GASTROENTEROLOGY, vol. 132, no. 4, April 2007 (2007-04-01), pages 1615 - 1618 *

Also Published As

Publication number Publication date
WO2009035497A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
IL254692A0 (en) Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009035497A3 (en) Disease related cysteine modifications and uses thereof
BRPI0817478A2 (en) orally bioavailable composition, methods for producing an orally bioavailable composition, and for treating a disease in a human, and, kit.
BRPI0807857A2 (en) TREATMENT OF IMMUNE DISEASE THROUGH DISTRIBUTION THROUGH ANTIGEN MUCOSA.
BRPI0818799A2 (en) Compositions for the treatment of parkinson's disease
BRPI0813725A2 (en) METHODS AND COMPOSITIONS FOR DISEASE TREATMENT
BRPI0816175A2 (en) SUITABLE COMPOSITIONS FOR TREATMENT OF SPINE DISEASE, DISORDER OR CONDITION.
RU2430111C3 (en) ANTIBODY MOLECULES WITH IMPROVED PROPERTIES
DK2155866T3 (en) MODIFIED PHOSPHATASES
TR201000668T1 (en) POLYPEPTIDE-NUCLEIC ACID CONJUGATE FOR IMMUNOPROPHILACY OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
ES2352576T8 (en) INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION.
EA200802208A1 (en) APPLICATION OF FLIBANSTERIN FOR THE TREATMENT OF DISEASES OF THE SEXUAL TREATMENT IN THE POST-CLIMACTERNIC PERIOD
BRPI0909541A2 (en) '' method for treating inflammatory bowel disease ''
WO2007007173A3 (en) Human anti-madcam antibodies
PL2172450T3 (en) Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
CL2007002199A1 (en) COMPOUNDS DERIVED FROM SULFONIL AMIDA, RECEIVER MODULATORS CB2; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT INFLAMMATORY AND AUTOINMUNE DISEASES.
BRPI0918876A2 (en) compositions for the prevention and treatment of dermatological / mucosal disease, and their uses
BRPI0820967A2 (en) Use of a composition, pharmaceutical composition and method for treating, ameliorating or prophylaxis of the symptoms of an inflammatory disease.
EP2107870A4 (en) Improved reduced irritant enema for the treatment of inflammatory bowel disease (ibd)
BRPI1012051A2 (en) "oral care composition, polymeric matrix film, and methods for preparing the film, and for treating an oral cavity disease or condition"
EA201001781A1 (en) Use of glycosaminoglycans for oral administration and composition of glycosaminoglycans
BRPI0910737A2 (en) compound, prodrug, pharmaceutical agent, method for prophylaxis or treatment of lower urinary tract diseases in a mammal, and use of a compound or a prodrug thereof.
EA200900259A1 (en) TREATMENT OF RHEUMATOID DISEASE BY GLUKOCORTICOIDES WITH RELAXED DELIVERY
FR2919999B1 (en) HYALURONIC ACID COMPOSITIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830251

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830251

Country of ref document: EP

Kind code of ref document: A2